Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
prostate cancer
Biotech
FDA to end 9-month adcomm hiatus with review of AZ cancer drugs
The April 30 event is also the first ODAC meeting after longtime FDA oncology czar Richard Pazdur, M.D., suddenly retired in December.
Angus Liu
Mar 6, 2026 11:16am
BioNTech’s B7-H3 ADC hits ph. 3 at half the size of Merck’s
Feb 27, 2026 10:31pm
Astellas says 'I do' to Vir's T-cell engager in $1.7B deal
Feb 23, 2026 5:00pm
Candel glows with $100M RTW deal to fund cancer drug launch
Feb 20, 2026 4:04am
Lilly drops 3 clinical programs, including Prevail gene therapy
Feb 4, 2026 12:33pm
FDA clears Francis Medical's water vapor prostate tumor ablation
Dec 10, 2025 9:25am